Niraparib (Zejula) for first line Ovarian Cancer - Details


( Last Updated : April 29, 2021)
Generic Name:
Niraparib
Project Status:
Complete
Therapeutic Area:
First Line OC
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Zejula
Project Line:
Reimbursement Review
Project Number:
PC0224-000
NOC Date:

Details


Strength:
100 mg
Tumour Type:
Gynecology
Indications:
Ovarian Cancer
Funding Request:
Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
Review Status:
Final Recommendation Posted
Pre Noc Submission:
Yes
Sponsor:
GlaxoSmithKline Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.